Zoledronic acid given upfront maintains BMD in postmenopausal breast cancer patients
How to Cite
OrthoEvidence. Zoledronic acid given upfront maintains BMD in postmenopausal breast cancer patients. ACE Report. 2013;2(8):33. Available from: https://myorthoevidene.com/AceReport/Report/4488
Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozoleCancer. 2012 Mar 1;118(5):1192-201. doi: 10.1002/cncr.26313. Epub 2011 Oct 10
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Dr. Adam M. Brufsky discusses the use of adjuvant zoledronic acid to maintain bone mass in postmenopausal breast cancer patients.
602 postmenopausal women receiving adjuvant letrozole were randomized either to upfront zoledronic acid or delayed-start zoledronic acid to determine which method minimizes bone-loss. At 5 years follow-up, upfront zoledronic acid was better at maintaining bone mineral density (BMD) in postmenopausal breast cancer patients than the delayed start technique.
Continuing Medical Education Credits
You could be earning 0.5 CME credits for each report you read.LEARN MORE